Company news

Krystal Biotech, Inc. news in 2021

Krystal Biotech, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock

November 29, 2021

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

November 28, 2021

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

November 28, 2021

Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting

November 18, 2021

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

November 7, 2021

Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

October 25, 2021

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

October 18, 2021

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

October 13, 2021

Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

October 11, 2021

Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

September 30, 2021

Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis

September 28, 2021

Krystal Biotech Appoints Laurent Goux as General Manager of Europe

September 14, 2021

Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021

September 8, 2021

Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

August 8, 2021

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

June 30, 2021

Krystal Biotech to Participate in Upcoming Investor Conferences

June 2, 2021

Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

May 9, 2021

Krystal Biotech Appoints Andy Orth as Chief Commercial Officer

May 2, 2021

Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT

April 26, 2021

Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB

April 25, 2021

Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline

April 18, 2021

Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

March 29, 2021

Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications

March 23, 2021

Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

February 28, 2021

Krystal Biotech to Present at the Cowen 41st Annual Health Care Conference

February 22, 2021

Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock

February 1, 2021

Krystal Biotech Announces Pricing of Upsized $125 Million Public Offering of Common Stock

February 1, 2021

Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors

January 3, 2021

Decks in 2021